La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Amylyx Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Amylyx Pharma..

Amylyx Pharma (NASDAQ:AMLX) Azioni, Catena delle Opzioni

Amylyx Pharma

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals Inc

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Hold.

News

Reiteration

Analyst Ratings

GILD

Needham Reiterates Hold on Gilead Sciences

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587386a45064ed0001b4b61b/lauren-lieberman">Barclays analyst Lauren Lieberman</a> downgraded the rating for Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) from Equal-Weight to Underweight and lowered the price target from $8 to $7. Coty shares closed at $7.43 on Wednesday. <a href="https://www.benzinga.com/quote/COTY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sean Milligan downgraded Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Hold to Underperform and cut the price target from $93 to $61. Enphase Energy shares closed at $74.81 on Wednesday. <a href="https://www.benzinga.com/quote/ENPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Laura Champine downgraded the rating for Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) from Buy to Hold and lowered the price target from $150 to $110. Crocs shares closed at $102.74 on Wednesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Toni Sacconaghi downgraded Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Outperform to Market Perform and announced a price target of $11. Ford shares closed at $11.19 on Wednesday. <a href="https://www.benzinga.com/quote/F/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59009b5a0bd9910001e5f2aa/bradley-thomas">Keybanc analyst Bradley Thomas </a>downgraded the rating for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from Overweight to Sector Weight. Dollar Tree shares closed at $62.41 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Ford stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-1024x586.png" alt="" class="wp-image-635158" style="width:545px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

COTY

CROX

DLTR

ENPH

This Ford Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

NKT Photonics to deliver three innovative prototype optical subsystems to IonQ in 2025
NKT Photonics' advanced laser systems will be integrated into IonQ's upcoming data center-ready quantum systems
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leader in the quantum computing industry, announced today a partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nktphotonics.com%2F&amp;esheet=54148577&amp;newsitemid=20241107761716&amp;lan=en-US&amp;anchor=NKT+Photonics&amp;index=1&amp;md5=e2aeed3e06c83873b1e9149d1f342cf4">NKT Photonics</a>, a subsidiary of Hamamatsu Photonics, to procure next-generation laser systems for IonQ's trapped-ion quantum computers and networking equipment. The partnership involves NKT Photonics developing and delivering three prototype optical subsystems to IonQ in 2025, designed to support the commercialization of IonQ's data center-ready quantum computers – such as IonQ Tempo and future barium-based systems.

IONQ

IonQ Announces Partnership With NKT Photonics For Next-Generation Laser Systems To Power Future Quantum Computers

Guidance

STGW

Stagwell Reaffirms FY24 Guidance For Organic Net Revenue Growth Of 5% To 7%; Adjusted EBITDA Of $400M - $450M; Free Cash Flow Conversion Of ~50%

Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 65.35 percent increase over losses of $(1.27) per share from the same period last year.

Earnings

Earnings Beats

LPCN

Lipocine Q3 EPS $(0.44) Beats $(0.48) Estimate

FSTR

L.B. Foster Sees FY 2024 Net Sales $530M-$540M Vs $540.92M Est.

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $207 price target.

Price Target

JAZZ

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target

General

COEP

Coeptis Therapeutics Announces Phase 1 Data On DVX201 For COVID-19 Treatment Has Been Accepted For Publication in 'Molecular Therapy Methods and Clinical Development'

WK Kellogg Raises FY24 Adj. EBITDA Guidance; Sees FY24 Adj. EBITDA Growth Of 5%-6%

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.72) by 11.11 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $354.62 million which beat the analyst consensus estimate of $225.00 thousand by 157.51K percent. This is a 110.90K percent increase over sales of $319.47 thousand the same period last year.

APRE

Aprea Therapeutics Q3 EPS $(0.64) Beats $(0.72) Estimate, Sales $354.62M Beat $225.00K Estimate

Endeavor Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>) reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.56 billion by 30.29 percent. This is a 51.12 percent increase over sales of $1.34 billion the same period last year.

Endeavor Q3 EPS From Cont. Ops $(0.44), Down From $(0.24) Last Year, Sales $2.03B, Up From $1.22B Prior Year

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) reported quarterly earnings of $3.27. The company reported quarterly sales of $137.50 million which missed the analyst consensus estimate of $141.78 million by 3.02 percent. This is a 5.40 percent decrease over sales of $145.34 million the same period last year.

Earnings Misses

L.B. Foster Q3 2024 GAAP EPS $3.27, Sales $137.50M Miss $141.78M Estimate

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.26 by 19.23 percent. The company reported quarterly sales of $689.000 million which beat the analyst consensus estimate of $674.044 million by 2.22 percent. This is a 0.43 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 2024 Adj. EPS $0.31 Beats $0.26 Estimate, Sales $689.000M Beat $674.044M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and maintains $100 price target.

KROS

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.42) by 23.81 percent. This is a 35.8 percent increase over losses of $(0.81) per share from the same period last year.

HLVX

HilleVax Q3 EPS $(0.52) Misses $(0.42) Estimate

Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 8.11 percent increase over losses of $(0.37) per share from the same period last year.

IMNN

Imunon Q3 2024 GAAP EPS $(0.34) Beats $(0.40) Estimate. Cash and Equivalents of $10.3M

Guidance
<ul>
<li>Q4 Consolidated Revenue expected to increase in the high-single digits</li>
<li>Full Year 2024 Consolidated Revenue expected to increase in the mid-single digits</li>
<li>Q4 Consolidated Adjusted EBITDA expected to be approximately $290 million, up approximately 39%</li>
<li>Full Year 2024 Consolidated Adjusted EBITDA expected to be approximately$750 million, up approximately 8%</li>
<li>Full Year 2025 Consolidated Revenue expected to be approximately flat in a non-political year</li>
<li>Full Year 2025 Consolidated Adjusted EBITDA3 expected to be approximately$770 million, up approximately 3% in a non-political year</li>
</ul>

IHRT

iHeartMedia Expects Q4 Revenue Growth Of High-Single Digits Vs $1.00B Est, Reiterated FY24 Revenue Growth Of Mid-Single Digits Vs $3.92B Est, FY25 Revenue Growth Of Approx Flat Vs $3.86B Est

Offerings

BYND

Beyond Meat Files To Offer And Sell Common Stock Having Offering Price Of Up To $20M From Time To Time Through Or To Sales Agent

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">Copa Holdings, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>)</h3>
<ul>
<li>Dividend Yield: 6.58%</li>
<li>TD Cowen analyst Thomas Fitzgerald maintained a Buy rating and cut the price target from $145 to $130 on Aug. 9. This analyst has an accuracy rate of 61%.</li>
<li>Deutsche Bank analyst Michael Linenberg maintained a Buy rating and slashed the price target from $145 to $130 on Aug. 8. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: Copa Holding will release third-quarter results on Nov. 20.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> latest CPA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71.png" alt="" class="wp-image-634808" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71-768x697.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Genco Shipping &amp; Trading Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNK#NYSE">GNK</a>)</h3>
<ul>
<li>Dividend Yield: 9.54%</li>
<li>Stifel analyst Benjamin Nolan downgraded the stock from Buy to Hold and cut the price target from $26 to $17 on Oct. 23. This analyst has an accuracy rate of 69%.</li>
<li>B. Riley Securities analyst Liam Burke maintained a Buy rating and increased the price target from $27 to $30 on May 10. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 6, Genco Shipping &amp; Trading posted downbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> to latest GNK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72.png" alt="" class="wp-image-634809" style="width:706px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72-768x706.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Karat Packaging Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul>
<li>Dividend Yield: 5.40%</li>
<li>Truist Securities analyst Jake Bartlett downgraded the stock from Buy to Hold rating and cut the price target from $34 to $28 on Aug. 9. This analyst has an accuracy rate of 77%.</li>
<li>Stifel analyst Michael Hoffman reiterated a Buy rating ad increased the price target from $30 to $32 on March 15. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On Nov. 6, Karat Packaging raised its quarterly dividend from 35 cents to 40 cents per share.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> trend in KRT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73.png" alt="" class="wp-image-634810" style="width:711px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73-768x702.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li>Jim Cramer: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Dividends

Wall Street's Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields

Biotech

Health Care

QNRX

Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025

Amylyx Pharmaceuticals, Inc. (AMLX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Amylyx Pharmaceuticals, Inc. is poi...

Amylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility

Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA – Research Report) ...

Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Amylyx Pharmaceuticals Inc (AMLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intra-Cellular Therapies (ITCI – Research Report), Amylyx Pharmac...

Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on AMLX stock, giving a Hold rating on October 17. Graig Suvannavej...

Neutral Stance on Amylyx Pharmaceuticals Amid Promising Data and Uncertainties

As previously reported, BofA analyst Charlie Yang upgraded Amylyx (AMLX) to Buy from Neutral with a price target of $10, up from $4.20, based on th...

Amylyx upgraded to Buy at BofA on 'underappreciated' PBH opportunity

BofA upgraded Amylyx (AMLX) to Buy from Neutral with a $10 price target Published first on TheFly – the ultimate source for real-time, market-movin...

Amylyx upgraded to Buy from Neutral at BofA

Bank of America Securities analyst Charlie CY Yang maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX – Research Report) today. The compan...

Bank of America Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM – Research Report), GlaxoSmithKline (GSK – Research ...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

AMLX

INGN

INSM

ISRG

ITCI

NMRA

NRGV

VTYX

Press Releases

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Legal

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Comments

Amylyx Pharma

Amylyx Pharma (AMLX) Opzioni

Amylyx Pharma (NASDAQ:AMLX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO